Why Newborn Mice Heal Spinal Cord Injuries That Paralyze Adults

Based on research from Johns Hopkins University, published in Bone Research (February 2026)

Every year in the United States, roughly 18,000 people sustain a spinal cord injury. An estimated 300,000 Americans currently live with some form of spinal cord damage, facing limited options for recovery. Despite decades of research into nerve regeneration, stem cell therapy, and rehabilitative strategies, the adult spinal cord remains stubbornly resistant to meaningful repair. A new study from Johns Hopkins University may finally explain why—and the answer lies in an unexpected comparison between newborn and adult biology.

Key Discovery

A research team led by Prof. Xu Cao and Dr. Dayu Pan at Johns Hopkins has identified transforming growth factor beta-1 (TGF-β1) as a central driver of the fibrotic scarring that prevents spinal cord recovery in adult mammals. Published in Bone Research in February 2026, the study reveals a striking age-dependent difference: neonatal mice that sustain spinal cord injuries recover almost completely, while adult mice develop dense fibrotic scars that permanently block nerve regrowth.

The critical difference, the team found, comes down to macrophages—immune cells that flood the injury site in both young and adult animals. In adults, these macrophages release large quantities of TGF-β1, which activates nearby stromal cells and triggers them to produce excessive collagen and extracellular matrix proteins. The result is a thick fibrotic scar that acts as both a physical and chemical barrier to axon regeneration. In neonatal mice, macrophages behave differently: they arrive at the injury but do not activate the TGF-β1 signaling cascade, allowing the tissue to heal without dense scarring.

When the researchers blocked TGF-β1 signaling in adult mice after spinal cord injury, the results were notable. Fibrotic scar formation was significantly reduced, and the animals showed measurable improvements in motor function compared to untreated controls. The intervention did not eliminate scarring entirely, but it shifted the injury response closer to the regenerative pattern observed in neonates.

Why This Matters

The fibrotic scar has long been recognized as one of the most formidable obstacles to spinal cord repair. Unlike the glial scar—formed by reactive astrocytes and already the target of therapies such as chondroitinase ABC, an enzyme that digests inhibitory scar molecules—the fibrotic scar is produced by non-neural stromal cells and creates a dense connective tissue barrier at the injury core. Previous work has shown that even when neurons are coaxed to extend new axons, these fibers frequently stall at the fibrotic scar boundary.

By pinpointing TGF-β1 from macrophages as the upstream trigger, the Johns Hopkins study offers a specific molecular target rather than a broad anti-inflammatory approach. This distinction matters because general immunosuppression after spinal cord injury can interfere with debris clearance and protective immune functions that are necessary for any recovery at all. A targeted strategy against TGF-β1 could, in theory, reduce harmful scarring while preserving beneficial aspects of the immune response.

The finding also complements ongoing work in stem cell therapy for spinal cord injury. Several clinical trials have transplanted neural progenitor cells or oligodendrocyte precursors into damaged spinal cords, with mixed results. One persistent challenge is that transplanted cells struggle to integrate and extend connections through scar tissue. If fibrotic scarring can be reduced at the molecular level, stem cell therapies and other regenerative approaches could become substantially more effective.

The Bigger Picture

The neonatal recovery observed in this study fits within a broader pattern in regenerative biology. Young mammals—and especially neonates—demonstrate remarkable healing capacities that diminish rapidly with age. Neonatal mice can regenerate heart tissue after injury, a capacity lost within the first week of life. Similar age-dependent differences have been documented in peripheral nerve repair and skin wound healing.

What makes the spinal cord finding particularly valuable is the identification of a specific molecular switch that distinguishes regenerative from fibrotic outcomes. TGF-β1 is not an unfamiliar molecule. It plays well-documented roles in wound healing, fibrosis, and immune regulation throughout the body. Aberrant TGF-β signaling has been implicated in pulmonary fibrosis, liver cirrhosis, and kidney disease, and drugs targeting the TGF-β pathway are already in clinical development for several of these conditions. This existing pharmaceutical groundwork could potentially accelerate the path toward spinal cord applications.

The study also raises important questions about the timing of intervention. The macrophage-driven TGF-β1 surge occurs relatively early after injury, suggesting that any therapeutic window for blocking fibrotic scar formation may be narrow. Understanding exactly when and how aggressively to intervene will be essential for translating these findings into clinical protocols.

Additionally, the research intersects with growing interest in anti-scarring strategies across the neuroscience field. Other groups have explored approaches ranging from enzyme-based scar digestion to biomaterial scaffolds that physically prevent scar accumulation. The TGF-β1 pathway offers a complementary angle—one that targets the signaling that initiates scarring rather than attempting to remove scar tissue after it has already formed.

Limitations and What Comes Next

Several important caveats apply to these findings. First, the work was conducted entirely in mouse models. While mice share many fundamental biological mechanisms with humans, the spinal cord injury response in larger mammals—including the scale of the injury, the complexity of the immune response, and the distances over which axons must regenerate—differs in meaningful ways. Results that look promising in rodents have historically faced significant hurdles in translation to human patients.

Second, TGF-β1 is not solely a harmful molecule. It plays essential roles in immune regulation, tissue homeostasis, and bone remodeling throughout the body. Systemic blockade of TGF-β1 could produce serious side effects, including immune dysfunction and impaired wound healing at other sites. Any clinical application would likely require highly localized delivery to the injury site, a technical challenge that adds complexity to therapeutic development.

Third, reducing fibrotic scarring is necessary but probably not sufficient for meaningful spinal cord recovery in humans. Even in the absence of fibrotic scar, adult central nervous system neurons face intrinsic barriers to regeneration, including low expression of growth-associated genes and the presence of myelin-associated inhibitors. A successful therapy would likely need to combine anti-fibrotic treatment with strategies that promote axonal growth and guide regenerating fibers to appropriate targets.

The research team has indicated that next steps include testing TGF-β1 inhibition in larger animal models and exploring localized delivery methods that could minimize off-target effects. Combinatorial approaches—pairing TGF-β1 blockade with chondroitinase treatment, rehabilitation protocols, or cell transplantation—are also under consideration.

At a Glance

• Fibrotic scarring driven by macrophage-released TGF-β1 is a major barrier to spinal cord recovery in adult mammals.
• Neonatal mice recover from spinal cord injuries without activating the TGF-β1 signaling cascade, avoiding dense scar formation.
• Blocking TGF-β1 in adult mice reduced fibrotic scarring and improved motor function after spinal cord injury.
• The finding identifies a specific molecular target rather than relying on broad immunosuppression.
• TGF-β pathway drugs already in development for other fibrotic diseases could accelerate clinical translation.
• Limitations include the mouse-only model, TGF-β1's essential roles elsewhere in the body, and the need for combination therapies.